Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Just the Facts: Cyprium Metals, Orthocell, American Rare Earths, Lumos Diagnostics

Just the Facts: Cyprium Metals, Orthocell, American Rare Earths, Lumos Diagnostics

In today's Just the Facts...

Cyprium Metals has officially greenlit the restart of cathode production at its Nifty Copper Complex in WA — a major step towards first copper production by mid-2026.

Orthocell is fast-tracking a new commercial pathway for its Remplir nerve repair device as more Australian urologists use it during prostate cancer surgery. About 100 procedures have already adopted Remplir.

American Rare Earths has expanded its partnership with engineering giant Tetra Tech to pursue US government funding for the Halleck Creek project. Tetra Tech already leads the project’s technical work, and this move aims to boost federal support as the US races to secure domestic rare-earth supply.

Lumos Diagnostics has strengthened its US rollout of its FebriDx respiratory test, signing a new partnership with American data group AcuityMD. The move gives Lumos clearer insight into reimbursement trends — a major barrier for diagnostics — as it expands FebriDx pilots across US primary clinics and urgent care centres.

ASXNews #Mining #MedicalTech #RareEarths #Copper #Biotech #Diagnostic

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK